What is the recommended ticagrelor (Brilinta) dosing regimen for patients with chronic coronary syndrome?

Ticagrelor Dosing in Chronic Coronary Syndrome

For patients with chronic coronary syndrome (CCS) but no prior stroke or myocardial infarction, administer ticagrelor 60 mg twice daily in combination with low-dose aspirin 75-100 mg daily. 1

Standard Dosing Regimen

• Ticagrelor 60 mg twice daily is the FDA-approved dose for CCS patients without prior MI or stroke, typically combined with aspirin 75-100 mg daily 1
• This lower maintenance dose (60 mg BID) differs from the acute coronary syndrome dosing, where 90 mg BID is used during the first year after an ACS event 1
• The 60 mg twice-daily regimen was specifically validated in the THEMIS trial population, which predominantly included patients with type 2 diabetes and established coronary artery disease 1

Post-MI or Post-ACS Dosing

If your CCS patient has a history of myocardial infarction, the dosing strategy changes:

• Loading dose: 180 mg once 1
• First year maintenance: 90 mg twice daily (first dose given 6-12 hours after loading) 1
• After one year: reduce to 60 mg twice daily for long-term secondary prevention 1
• Always combine with aspirin 75-100 mg daily 1

Critical Guideline Restrictions

Ticagrelor is generally NOT recommended in specific CCS scenarios:

• Do not use ticagrelor as part of triple antithrombotic therapy (ticagrelor + aspirin + oral anticoagulant) in patients requiring anticoagulation—this carries a Class III (harm) recommendation from the ESC 2, 3, 4
• In CCS patients with atrial fibrillation or other anticoagulation indications who undergo PCI, use clopidogrel (not ticagrelor) as the P2Y12 inhibitor during the dual-therapy phase 2, 3
• After the initial post-PCI period (≤1 week of triple therapy, then up to 6-12 months of dual therapy), transition to oral anticoagulant monotherapy 3

Aspirin Co-Administration

• Maintain aspirin at 75-100 mg daily—higher doses should be avoided as they may reduce ticagrelor's efficacy 1
• In post-PCI patients, consider transitioning to ticagrelor monotherapy (without aspirin) based on evolving thrombotic versus bleeding risk, though this is an emerging strategy 1

Administration Considerations

• For patients unable to swallow tablets: crush ticagrelor, mix with water, and administer orally or via nasogastric tube (≥CH8) 1
• Never combine ticagrelor with another P2Y12 inhibitor (e.g., clopidogrel, prasugrel) 1
• If a dose is missed, take the next scheduled dose—do not double up 1

Safety Monitoring

• Dyspnea occurs in 14-21% of patients on ticagrelor and is usually mild-to-moderate, resolving with continued therapy; however, it leads to discontinuation in 4-6% of cases 1
• Bleeding risk is significantly increased: ticagrelor prolongs bleeding time more than rivaroxaban-based strategies 5
• Recent evidence shows ticagrelor increases chest pain/tightness by approximately 7.5 per 100 patients compared to clopidogrel 6

Comparative Efficacy in CCS

• Ticagrelor versus clopidogrel in CCS shows similar cardiovascular outcomes (mortality, MI, stroke) based on 2025 meta-analysis of 3,370 patients 6
• Ticagrelor may provide modest stroke prevention benefit in CCS, particularly with long-term use (>1 year) at the 60 mg BID dose, though this comes with increased intracranial hemorrhage risk 7
• After CABG for ACS, ticagrelor plus aspirin does not reduce cardiovascular events versus aspirin alone and significantly increases major bleeding (4.9% vs 2.0%), making aspirin monotherapy the preferred post-CABG strategy 8

Duration of Therapy

• Lifelong therapy is recommended for CCS patients at high ischemic risk, defined by ESC criteria (prior MI, multivessel disease, diabetes, chronic kidney disease, or recurrent ischemic events) 2, 3
• Ticagrelor monotherapy after 3 months of DAPT appears safe in both high and non-high ischemic risk CCS patients undergoing PCI, with similar rates of major adverse cardiac events compared to continued DAPT 9

Key Contraindications

• Active pathological bleeding (e.g., peptic ulcer, intracranial hemorrhage) 1
• History of intracranial hemorrhage 1
• Hypersensitivity to ticagrelor, including angioedema 1

Discontinuation Warnings

• Stopping ticagrelor increases risk of MI, stroke, and death in CAD patients 1
• If surgery is required, interrupt ticagrelor for 5 days before procedures with major bleeding risk, then restart as soon as hemostasis is achieved 1
• Never discontinue abruptly without restarting unless there is active bleeding or another absolute contraindication 1